Corporate News
Elanco Animal Health (NYSE: ELAN) closed the trading day on Wednesday, October 21, 2026, at a price of USD 22.51, reflecting a decline of –3.36 % from the prior close. The stock’s market value currently stands at USD 11.7 billion, with a circulating supply of 499.8 million shares. In the most recent 24‑hour window, approximately USD 187.2 million of Elanco shares changed hands, a figure that represents a modest +1.2 % increase compared to the month‑end snapshot. The 200‑day simple moving average sits at USD 23.83, while the 52‑week high and low were USD 27.98 (dated 05 08 2026) and USD 19.40 (dated 05 19 2026), respectively.
Insider Activity
Late‑October filings under SEC Form 4 revealed a series of routine executive transactions. The company’s senior officers—President, CEO, and Executive Vice Presidents—reported the acquisition of deferred stock units under the Executive Deferral and Stock Match Plan. The awards, granted on October 16 2026, carried a value of approximately USD 23.55 per unit, pushing each officer’s holdings beyond 25 000 shares. Separately, the Executive Vice President of Finance and the CEO exercised 62.7 and 120.0 deferred units, respectively, bringing their post‑transaction holdings to more than 10 000 shares each. Meanwhile, the Executive Vice President of Pet Health and the Chief Financial Officer purchased a modest number of units, raising his ownership to roughly 176 shares. An officer executed a Rule 10b‑5‑1 trade selling 4 350 shares on October 15, reducing his stake to about 139 000 shares.
Market Context
Elanco’s recent performance sits alongside a diverse set of peer movements:
| Stock | % Change | Current Price (USD) | Market Cap (USD) | Notable Recent Event |
|---|---|---|---|---|
| Trimble (TRMB) | +3.62 % | 62.44 | 14 bn | Upcoming Q3 2026 earnings call |
| Halozyme Therapeutics (HALO) | +1.53 % | 124.5 | 13.9 bn | First Student’s safety‑tech pilot highlighted |
| Guidewire Software (GWRE) | +7.08 % | 183.06 | 14.1 bn | Senior‑executive sales under a 10b‑5‑1 plan |
| TransUnion (TRU) | +6.99 % | 78.78 | 14 bn | New fraud‑risk metrics launched |
| Neurocrine Biosciences (NBIX) | +3.66 % | 141.28 | 13.9 bn | Phase 2 study of oral muscarinic agonist announced |
These movements illustrate a sector‑wide focus on technology, safety, and innovation, with Elanco’s share price reflecting both market‑wide volatility and company‑specific developments.
Company Overview
Elanco Animal Health Incorporated, headquartered in Greenfield, United States, is a global provider of products for companion and food animals. Since its initial public offering on September 20, 2018, the company has maintained a presence on the New York Stock Exchange and continues to expand its portfolio of therapeutics, diagnostics, and preventive measures aimed at improving animal health and welfare worldwide.
